Rita Nahta

Rita Nahta

UNVERIFIED PROFILE

Are you Rita Nahta?   Register this Author

Register author
Rita Nahta

Rita Nahta

Publications by authors named "Rita Nahta"

Are you Rita Nahta?   Register this Author

58Publications

1192Reads

15Profile Views

Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.

Clin Breast Cancer 2019 Sep 18. Epub 2019 Sep 18.

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.09.003DOI Listing
September 2019

Targeting forkhead box M1 transcription factor in breast cancer.

Biochem Pharmacol 2018 08 31;154:407-413. Epub 2018 May 31.

Departments of Pharmacology and Hematology & Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2018.05.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061948PMC
August 2018

ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.

Expert Opin Biol Ther 2018 03 24;18(3):335-341. Epub 2018 Jan 24.

a Department of Hematology & Medical Oncology, School of Medicine , Emory University , Atlanta, GA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2018.1430761DOI Listing
March 2018

Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling.

Oncotarget 2017 Nov 10;8(55):94393-94406. Epub 2017 Oct 10.

Molecular & Systems Pharmacology PhD Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706882PMC
November 2017

in medulloblastoma.

Oncoscience 2016 3;3(7-8):186-187. Epub 2016 Sep 3.

Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043068PMC
September 2016

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Authors:
Keith I Block Charlotte Gyllenhaal Leroy Lowe Amedeo Amedei A R M Ruhul Amin Amr Amin Katia Aquilano Jack Arbiser Alexandra Arreola Alla Arzumanyan S Salman Ashraf Asfar S Azmi Fabian Benencia Dipita Bhakta Alan Bilsland Anupam Bishayee Stacy W Blain Penny B Block Chandra S Boosani Thomas E Carey Amancio Carnero Marianeve Carotenuto Stephanie C Casey Mrinmay Chakrabarti Rupesh Chaturvedi Georgia Zhuo Chen Helen Chen Sophie Chen Yi Charlie Chen Beom K Choi Maria Rosa Ciriolo Helen M Coley Andrew R Collins Marisa Connell Sarah Crawford Colleen S Curran Charlotta Dabrosin Giovanna Damia Santanu Dasgupta Ralph J DeBerardinis William K Decker Punita Dhawan Anna Mae E Diehl Jin-Tang Dong Q Ping Dou Janice E Drew Eyad Elkord Bassel El-Rayes Mark A Feitelson Dean W Felsher Lynnette R Ferguson Carmela Fimognari Gary L Firestone Christian Frezza Hiromasa Fujii Mark M Fuster Daniele Generali Alexandros G Georgakilas Frank Gieseler Michael Gilbertson Michelle F Green Brendan Grue Gunjan Guha Dorota Halicka William G Helferich Petr Heneberg Patricia Hentosh Matthew D Hirschey Lorne J Hofseth Randall F Holcombe Kanya Honoki Hsue-Yin Hsu Gloria S Huang Lasse D Jensen Wen G Jiang Lee W Jones Phillip A Karpowicz W Nicol Keith Sid P Kerkar Gazala N Khan Mahin Khatami Young H Ko Omer Kucuk Rob J Kulathinal Nagi B Kumar Byoung S Kwon Anne Le Michael A Lea Ho-Young Lee Terry Lichtor Liang-Tzung Lin Jason W Locasale Bal L Lokeshwar Valter D Longo Costas A Lyssiotis Karen L MacKenzie Meenakshi Malhotra Maria Marino Maria L Martinez-Chantar Ander Matheu Christopher Maxwell Eoin McDonnell Alan K Meeker Mahya Mehrmohamadi Kapil Mehta Gregory A Michelotti Ramzi M Mohammad Sulma I Mohammed D James Morre Vinayak Muralidhar Irfana Muqbil Michael P Murphy Ganji Purnachandra Nagaraju Rita Nahta Elena Niccolai Somaira Nowsheen Carolina Panis Francesco Pantano Virginia R Parslow Graham Pawelec Peter L Pedersen Brad Poore Deepak Poudyal Satya Prakash Mark Prince Lizzia Raffaghello Jeffrey C Rathmell W Kimryn Rathmell Swapan K Ray Jörg Reichrath Sarallah Rezazadeh Domenico Ribatti Luigi Ricciardiello R Brooks Robey Francis Rodier H P Vasantha Rupasinghe Gian Luigi Russo Elizabeth P Ryan Abbas K Samadi Isidro Sanchez-Garcia Andrew J Sanders Daniele Santini Malancha Sarkar Tetsuro Sasada Neeraj K Saxena Rodney E Shackelford H M C Shantha Kumara Dipali Sharma Dong M Shin David Sidransky Markus David Siegelin Emanuela Signori Neetu Singh Sharanya Sivanand Daniel Sliva Carl Smythe Carmela Spagnuolo Diana M Stafforini John Stagg Pochi R Subbarayan Tabetha Sundin Wamidh H Talib Sarah K Thompson Phuoc T Tran Hendrik Ungefroren Matthew G Vander Heiden Vasundara Venkateswaran Dass S Vinay Panagiotis J Vlachostergios Zongwei Wang Kathryn E Wellen Richard L Whelan Eddy S Yang Huanjie Yang Xujuan Yang Paul Yaswen Clement Yedjou Xin Yin Jiyue Zhu Massimo Zollo

Semin Cancer Biol 2015 Dec;35 Suppl:S276-S304

Centro di Ingegneria Genetica e Biotecnologia Avanzate, Naples, Italy; Department of Molecular Medicine and Medical Biotechnology, Federico II, Via Pansini 5, 80131 Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2015.09.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819002PMC
December 2015

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Authors:
William H Goodson Leroy Lowe David O Carpenter Michael Gilbertson Abdul Manaf Ali Adela Lopez de Cerain Salsamendi Ahmed Lasfar Amancio Carnero Amaya Azqueta Amedeo Amedei Amelia K Charles Andrew R Collins Andrew Ward Anna C Salzberg Annamaria Colacci Ann-Karin Olsen Arthur Berg Barry J Barclay Binhua P Zhou Carmen Blanco-Aparicio Carolyn J Baglole Chenfang Dong Chiara Mondello Chia-Wen Hsu Christian C Naus Clement Yedjou Colleen S Curran Dale W Laird Daniel C Koch Danielle J Carlin Dean W Felsher Debasish Roy Dustin G Brown Edward Ratovitski Elizabeth P Ryan Emanuela Corsini Emilio Rojas Eun-Yi Moon Ezio Laconi Fabio Marongiu Fahd Al-Mulla Ferdinando Chiaradonna Firouz Darroudi Francis L Martin Frederik J Van Schooten Gary S Goldberg Gerard Wagemaker Gladys N Nangami Gloria M Calaf Graeme Williams Gregory T Wolf Gudrun Koppen Gunnar Brunborg H Kim Lyerly Harini Krishnan Hasiah Ab Hamid Hemad Yasaei Hideko Sone Hiroshi Kondoh Hosni K Salem Hsue-Yin Hsu Hyun Ho Park Igor Koturbash Isabelle R Miousse A Ivana Scovassi James E Klaunig Jan Vondráček Jayadev Raju Jesse Roman John Pierce Wise Jonathan R Whitfield Jordan Woodrick Joseph A Christopher Josiah Ochieng Juan Fernando Martinez-Leal Judith Weisz Julia Kravchenko Jun Sun Kalan R Prudhomme Kannan Badri Narayanan Karine A Cohen-Solal Kim Moorwood Laetitia Gonzalez Laura Soucek Le Jian Leandro S D'Abronzo Liang-Tzung Lin Lin Li Linda Gulliver Lisa J McCawley Lorenzo Memeo Louis Vermeulen Luc Leyns Luoping Zhang Mahara Valverde Mahin Khatami Maria Fiammetta Romano Marion Chapellier Marc A Williams Mark Wade Masoud H Manjili Matilde E Lleonart Menghang Xia Michael J Gonzalez Michalis V Karamouzis Micheline Kirsch-Volders Monica Vaccari Nancy B Kuemmerle Neetu Singh Nichola Cruickshanks Nicole Kleinstreuer Nik van Larebeke Nuzhat Ahmed Olugbemiga Ogunkua P K Krishnakumar Pankaj Vadgama Paola A Marignani Paramita M Ghosh Patricia Ostrosky-Wegman Patricia A Thompson Paul Dent Petr Heneberg Philippa Darbre Po Sing Leung Pratima Nangia-Makker Qiang Shawn Cheng R Brooks Robey Rabeah Al-Temaimi Rabindra Roy Rafaela Andrade-Vieira Ranjeet K Sinha Rekha Mehta Renza Vento Riccardo Di Fiore Richard Ponce-Cusi Rita Dornetshuber-Fleiss Rita Nahta Robert C Castellino Roberta Palorini Roslida Abd Hamid Sabine A S Langie Sakina E Eltom Samira A Brooks Sandra Ryeom Sandra S Wise Sarah N Bay Shelley A Harris Silvana Papagerakis Simona Romano Sofia Pavanello Staffan Eriksson Stefano Forte Stephanie C Casey Sudjit Luanpitpong Tae-Jin Lee Takemi Otsuki Tao Chen Thierry Massfelder Thomas Sanderson Tiziana Guarnieri Tove Hultman Valérian Dormoy Valerie Odero-Marah Venkata Sabbisetti Veronique Maguer-Satta W Kimryn Rathmell Wilhelm Engström William K Decker William H Bisson Yon Rojanasakul Yunus Luqmani Zhenbang Chen Zhiwei Hu

Carcinogenesis 2015 Jun;36 Suppl 1:S254-96

Department of Surgery, The Ohio State University College of Medicine, The James Comprehensive Cancer Center, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://carcin.oxfordjournals.org/content/36/Suppl_1/S254.ful
Web Search
http://carcin.oxfordjournals.org/content/36/Suppl_1/S254.ful
Web Search
http://www.ilcambiamento.it/files/carcinogenesi.pdf
Web Search
http://www.carcin.oxfordjournals.org/lookup/doi/10.1093/carc
Publisher Site
http://dx.doi.org/10.1093/carcin/bgv039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480130PMC
June 2015

Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?

Cancer 2015 Feb 24;121(4):517-26. Epub 2014 Oct 24.

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia; Department of Hematology and Medical Oncology, Emory University, Georgia Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29060DOI Listing
February 2015

Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.

Mol Pharmacol 2015 Feb 12;87(2):150-61. Epub 2014 Nov 12.

Departments of Pharmacology (E.S.-F., S.M.D., R.N.) and Hematology and Medical Oncology (E.P., L.T.-S., R.N.), School of Medicine, and Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences (E.S.-F., R.N.), and Winship Cancer Institute (R.C.C., E.P., L.T.-S., R.N.), Emory University, Atlanta, Georgia; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia (M.C.B., R.C.C.); and Departments of Obstetrics and Gynecology and Microbiology, James Cancer Hospital, Solove Research Institute and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio (K.C.F., P.T.P.K.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.114.095380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293451PMC
February 2015

IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Oncoimmunology 2014 Nov 21;3(11):e956005. Epub 2014 Dec 21.

Department of Obstetrics and Gynecology; The Ohio State University ; Columbus, OH USA ; Department of Microbiology; The Ohio State University ; Columbus, OH USA ; James Cancer Hospital and Solove Research Institute and the Comprehensive Cancer Center; The Ohio State University ; Columbus, OH USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21624011.2014.956005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368154PMC
November 2014

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Oncoimmunology 2014 Nov 21;3(11):e956012. Epub 2014 Dec 21.

Department of Microbiology; The Ohio State University , Columbus, OH USA ; Department of Obstetrics and Gynecology; The Ohio State University Wexner Medical Center ; Columbus, OH USA ; The James Cancer Hospital and Solove Research Institute; and the Comprehensive Cancer Center; The Ohio State University , Columbus, OH USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21624011.2014.956012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368151PMC
November 2014

Resistance to HER2-targeted therapies: a potential role for FOXM1.

Breast Cancer Manag 2014;3(5):423-431

Molecular & Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University ; Cancer Biology Program, Graduate Division of Biological and Biomedical Sciences, Emory University ; Department of Pharmacology, Emory University ; Department of Hematology and Medical Oncology, Emory University ; Winship Cancer Institute, Emory University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmt.14.33DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294221PMC
January 2014

Human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Authors:
Rita Nahta

Expert Opin Biol Ther 2013 Jul 9;13(7):949-52. Epub 2013 Apr 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2013.789497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161367PMC
July 2013

Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines.

Curr Pharmacogenomics Person Med 2013 Mar;11(1):31-41

Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA ; Winship Cancer Institute, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811155PMC
http://dx.doi.org/10.2174/1875692111311010006DOI Listing
March 2013

Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.

Biochem Pharmacol 2013 Jan 17;85(1):46-58. Epub 2012 Oct 17.

Department of Pharmacology, School of Medicine, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2012.10.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329765PMC
January 2013

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.

Authors:
Rita Nahta

ISRN Oncol 2012 22;2012:428062. Epub 2012 Nov 22.

Department of Pharmacology, School of Medicine Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA ; Department of Hematology and Medical Oncology, School of Medicine Emory University, Atlanta, GA 30322, USA ; Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA ; Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5402/2012/428062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512309PMC
December 2012

Catalytic deoxyribozyme-modified nanoparticles for RNAi-independent gene regulation.

ACS Nano 2012 Oct 18;6(10):9150-7. Epub 2012 Sep 18.

Department of Chemistry, Emory University, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/nn3034265
Publisher Site
http://dx.doi.org/10.1021/nn3034265DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482470PMC
October 2012

Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.

J Natl Cancer Inst 2012 Oct 5;104(20):1576-90. Epub 2012 Oct 5.

Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

View Article

Download full-text PDF

Source
http://www.oxfordjournals.org/our_journals/jnci/press_releas
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djs396
Publisher Site
http://dx.doi.org/10.1093/jnci/djs396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472971PMC
October 2012

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.

Breast Cancer Res Treat 2012 Aug 20;135(1):39-48. Epub 2012 Apr 20.

Department of Pharmacology, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2067-8DOI Listing
August 2012

Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.

Authors:
Rita Nahta

Chemother Res Pract 2012 9;2012:648965. Epub 2012 Jul 9.

Departments of Pharmacology, Hematology and Medical Oncology, School of Medicine; Winship Cancer Institute; Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/648965DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399380PMC
August 2012

New developments in the treatment of HER2-positive breast cancer.

Authors:
Rita Nahta

Breast Cancer (Dove Med Press) 2012 May;4:53-64

Departments of Pharmacology and Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S24976DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712518PMC
May 2012

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.

Anticancer Agents Med Chem 2012 Feb;12(2):151-62

Molecular & Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288300PMC
http://dx.doi.org/10.2174/187152012799015002DOI Listing
February 2012

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.

Curr Pharmacogenomics Person Med 2011 Sep;9(3):184-190

Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233239PMC
http://dx.doi.org/10.2174/187569211796957584DOI Listing
September 2011

Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism.

Cancer Res 2011 Jul 15;71(13):4585-97. Epub 2011 Apr 15.

Mitchell Cancer Institute, Department of Cell Biology and Neuroscience, University of South Alabama, Mobile, Alabama 36604, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-0127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129363PMC
July 2011

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Clin Breast Cancer 2010 Nov;10 Suppl 3:S72-8

Department of Pharmacology, Emory University,Winship Cancer Institute, 1365 Clifton Road, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.s.015DOI Listing
November 2010

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

Cancer Chemother Pharmacol 2010 Mar 28;65(4):697-706. Epub 2009 Jul 28.

Department of Pharmacology, Emory University School of Medicine, Suite 5001, 1510 Clifton Rd., Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1075-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808522PMC
March 2010

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.

Mol Cancer Ther 2008 Jul;7(7):1900-8

Department of Pharmacology, School of Medicine, Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586607PMC
July 2008

A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells.

Mol Cancer Res 2008 Jun 30;6(6):1052-8. Epub 2008 May 30.

Department of Pharmacology, Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-07-2126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440577PMC
June 2008

Her2 cross talk and therapeutic resistance in breast cancer.

Front Biosci 2008 May 1;13:3906-12. Epub 2008 May 1.

Department of Pharmacology, School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA 30322-1013, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746389PMC
http://dx.doi.org/10.2741/2978DOI Listing
May 2008

HER2 therapy: molecular mechanisms of trastuzumab resistance.

Breast Cancer Res 2006 ;8(6):215

Department of Breast Medical Oncology, Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr1612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797036PMC
February 2007

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

Mol Cancer Ther 2007 Feb;6(2):667-74

Department of Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-06
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-06-0423DOI Listing
February 2007

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.

Mol Cancer Ther 2007 Jan 11;6(1):227-35. Epub 2007 Jan 11.

Department of Stem Cell Transplantation and Cellular Therapy, Unit 448, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-05-0499DOI Listing
January 2007

B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.

Mol Cancer Ther 2006 Jun;5(6):1593-601

Department of Breast Medical Oncology, Unit 1354, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0133DOI Listing
June 2006

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nat Clin Pract Oncol 2006 May;3(5):269-80

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc0509DOI Listing
May 2006

Herceptin: mechanisms of action and resistance.

Cancer Lett 2006 Feb;232(2):123-38

Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2005.01.041DOI Listing
February 2006

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

Cancer Res 2005 Dec;65(23):11118-28

Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-3841DOI Listing
December 2005

TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein.

Mol Cancer Res 2004 Aug;2(8):442-52

Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
August 2004

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

Cancer Res 2004 Jun;64(11):3981-6

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-03-3900DOI Listing
June 2004

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

Cancer Res 2004 Apr;64(7):2343-6

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.can-03-3856DOI Listing
April 2004

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

Cancer Chemother Pharmacol 2004 Feb 7;53(2):186-90. Epub 2003 Nov 7.

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0728-3DOI Listing
February 2004

HER-2-targeted therapy: lessons learned and future directions.

Clin Cancer Res 2003 Nov;9(14):5078-84

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
November 2003

Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer.

Semin Oncol 2003 Oct;30(5 Suppl 16):143-9

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.08.016DOI Listing
October 2003

Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.

Cancer Res 2003 Jul;63(13):3626-31

Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
July 2003

Novel pharmacological approaches in the treatment of breast cancer.

Expert Opin Investig Drugs 2003 Jun;12(6):909-21

Department of Molecular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/13543784.12.6.90
Publisher Site
http://dx.doi.org/10.1517/13543784.12.6.909DOI Listing
June 2003

Growth factor receptors in breast cancer: potential for therapeutic intervention.

Oncologist 2003 ;8(1):5-17

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.8-1-5DOI Listing
May 2003

Signal transduction inhibitors in the treatment of breast cancer.

Curr Med Chem Anticancer Agents 2003 May;3(3):201-16

Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568011033482468DOI Listing
May 2003

Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.

Cancer Res 2002 Apr;62(8):2267-71

Laboratory of Tumor Biology, Massachusetts General Hospital Cancer Center, Building 149, 13th Street, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
April 2002